The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Approval of exa-cel for SCD
Haydar Frangoul, MD, The Children’s Hospital at TriStar Centennial, Nashville, TN, talks about the approval of exagamglogene autotemcel (exa-cel) for patients with sickle cell disease (SCD) and its potential application in β-thalassemia. He expresses optimism for the efficacy of this therapy to be sustained long-term and increased accessibility to a broader patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
